Psychotropic drug-induced genetic-epigenetic modulation of CRCT1 gene is associated with early weight gain in a prospective study of psychiatric patients

Aurélie Delacrétaz 1, Anaïs Glatard 1, Céline Dubath 1, Mehdi Gholam-Rezaee 2, Jose Vicente Sanchez-Mut 3, Johannes Gräff 3, Armin von Gunten 4, Philippe Conus 5 and Chin B. Eap 1,6*

Abstract

**Background:** Metabolic side effects induced by psychotropic drugs represent a major health issue in psychiatry. CREB-regulated transcription coactivator 1 (CRCT1) gene plays a major role in the regulation of energy homeostasis and epigenetic mechanisms may explain its association with obesity features previously described in psychiatric patients. This prospective study included 78 patients receiving psychotropic drugs that induce metabolic disturbances, with weight and other metabolic parameters monitored regularly. Methylation levels in 76 CRCT1 probes were assessed before and after 1 month of psychotropic treatment in blood samples.

**Results:** Significant methylation changes were observed in three CRCT1 CpG sites (i.e., cg07015183, cg12034943, and cg 17006757) in patients with early and important weight gain (i.e., equal or higher than 5% after 1 month; FDR p value = 0.02). Multivariable models showed that methylation decrease in cg12034943 was more important in patients with early weight gain (≥ 5%) than in those who did not gain weight (p = 0.01). Further analyses combining genetic and methylation data showed that cg12034943 was significantly associated with early weight gain in patients carrying the G allele of rs4808844A>G (p = 0.03), a SNP associated with this methylation site (p = 0.03).

**Conclusions:** These findings give new insights on psychotropic-induced weight gain and underline the need of future larger prospective epigenetic studies to better understand the complex pathways involved in psychotropic-induced metabolic side effects.

**Keywords:** Early weight gain, Psychotropic drugs, CRCT1, Methylation, Psychiatric population

Background

Metabolic diseases such as obesity or dyslipidemia arise from a complex interplay between genetic and environmental factors. During the last two decades, many efforts were put into understanding how genetic and environmental factors interact in the development of cardiometabolic diseases. Recently, epigenetic mechanisms have been proposed to link the genetic background with environmental influences, placing important expectations on the potential to unravel mechanisms of cardiometabolic diseases [1–6]. In psychiatry, patients suffering from schizophrenia, bipolar disorder, and major depressive disorders have a reduced life expectancy of 10–15 years compared to individuals from the general population [7, 8], which is mainly attributable to cardiovascular diseases resulting from the metabolic syndrome [9]. Multiple risk factors implying complex mechanisms may explain this excessive susceptibility for developing metabolic diseases, including psychiatric disease-related factors, unhealthy lifestyle, genetic susceptibilities, and adverse effects of treatment [10–12]. Thus, the use of psychotropic medications such as
antipsychotics (most atypical but also some typical), mood stabilizers (e.g., lithium), and some antidepressants (e.g., mirtazapine) can increase the risk of metabolic disorders, including obesity and dyslipidemia [13, 14]. Metabolic side effects induced by psychotropic drugs result from an appetite increase driven by multiple mechanisms, including pharmacodynamic affinities as well as modifications in the transcription of some hormones involved in energy homeostasis [15, 16]. Although epigenetic mechanisms underlying side effects induced by psychotropic treatments are yet very poorly understood, some studies have determined methylation changes associated with atypical antipsychotics [17–19] and mood stabilizers [20–22], some of which were linked with the recovery of molecular aberrations observed in patients with psychiatric diseases [23]. Concerning metabolic side effects, two recent studies have drawn attention to associations between certain methylation sites and insulin resistance [24, 25]. However, it is unknown whether methylation modulations are tissue-specific and/or reversible. More importantly, epigenetic studies conducted in longitudinal settings are lacking.

Worsening of the metabolic condition may develop early during treatment with psychotropic drugs inducing metabolic disturbances [26–29] and may initiate a steady process leading to cardiometabolic diseases in the long term. This underlines the importance to prospectively monitor metabolic parameters in particular during the first months of treatment [30]. Of note, some studies using prospective weight data determined that a weight gain of 5% or more during the first month of treatment could robustly predict subsequent important weight gain [26] and metabolic syndrome [31].

Over the last decade, pharmacogenetics of psychotropic-induced weight gain has been extensively studied using candidate gene approaches, in particular within dopamine and serotonin receptors [32, 33]. In addition, numerous single nucleotide polymorphisms (SNPs) within genes involved in other pathways of metabolism (e.g., in enzymes, receptors, or transcriptional coactivators involved in food intake homeostasis) were also associated with weight gain in psychiatric patients receiving psychotropic drugs [34–38]. In particular, animal and human studies have identified the CREB-regulated transcription coactivator 1 (CRTC1) as an interesting candidate gene. Thus, mice lacking this gene developed obesity and other metabolic complications under normal diets [39–41]. Furthermore, while becoming obese, CRTC1 knockout male mice on a normal chow diet were hyperphagic and had alterations in the expression of orexigenic and anorexigenic genes, underlining the key role of CRTC1 in the regulation of food intake [42]. Interestingly, other studies showed that CRTC1 knockout mice exhibit neurobehavioral endophenotypes related to mood disorders, depression-related behavior, and a blunted behavioral response to antidepressants [43]. Thus, growing evidence supports the hypothesis that obesity and depression may originate from shared biological pathways [44–46]. In human, we showed that a nonsense mutation in CRTC1 (i.e., rs3746266A>G) is associated with body mass index in psychiatric patients treated with weight gain-inducing psychotropic drugs and in the general population [38]. Later on, a population-based study demonstrated that the influence of this SNP on obesity features was exclusively applicable in individuals with lifetime depression [47]. Finally, in a recent genome-wide association meta-analysis on body fat percentage in more than 100,000 individuals from the general population, CRTC1 reached genome-wide significance and epigenetic mechanisms were suggested to explain this association [48].

These abovementioned aspects prompted us to investigate the influence of psychotropic drugs on CRTC1 epigenetic modulation and to determine whether such modulations are associated with the risk of gaining weight and/or with CRTC1 genetic polymorphism. For this purpose, methylation levels in 76 CRTC1 probes were measured in DNA extracted from blood samples drawn in psychiatric patients before the initiation of weight gain inducing psychotropic drugs and after the first month of treatment, using each patient as his own control to dissociate the epigenetic effect from the genetic background. Data were compared between two groups of patients with extreme phenotypes, i.e., those developing early (after 1 month) and important (≥ 5%) weight gain (considered as “cases”) and those with no or minimal weight change (considered as “controls”).

**Results**

**Demographics and CRTC1 methylation sites**

The course of methylation levels during the first month of psychotropic treatment in 78 patients was investigated in 76 CRTC1 probes (as listed in Additional file 1: Table S1). Median age was 37 years (IQR = 27–51 years), half of the patients were men (n = 39, 50%) and half of the patients smoked (n = 39, 50%) (Table 1). Psychotic disorders were the most frequent diagnosis (n = 35, 45%) and quetiapine was the most frequently prescribed psychotropic drug (n = 23, 30%). Half of the patients received psychotropic drugs with a moderate propensity for inducing weight gain (i.e., lithium, mirtazapine, quetiapine or risperidone, n = 42, 54%), while one-third received psychotropic drugs having a high risk for inducing weight gain (i.e., clozapine, olanzapine, or valproate, n = 24, 30%). One-third of patients was already overweight at baseline (n = 24, 31%) and this prevalence significantly increased during the first month of psychotropic treatment (n = 28, 36%, p = 0.04). A higher proportion of smokers (64% versus 37%; p = 0.02) was observed in control patients (i.e., patients without weight gain during the first month of treatment) than in case patients (i.e., patients with important weight gain during the same period). As expected,
|                              | N   | All patients (n = 78) | Controls¹ (n = 39) | Cases¹ (n = 39) | p value² |
|------------------------------|-----|----------------------|--------------------|----------------|----------|
| Age, median (IQR), years     | 78  | 37 (27–51)           | 40 (28–56)         | 37 (25–50)     | 0.47     |
| Men, n (%)                   | 78  | 39 (50.0)            | 19 (48.7)          | 20 (51.3)      | 0.82     |
| Smoking at baseline, n (%)   | 74  | 37 (50.0)            | 23 (63.9)          | 14 (36.8)      | 0.02     |
| Diagnosis, n (%)             |     |                      |                    |                |          |
| Psychotic disorders          | 78  | 35 (44.9)            | 17 (43.6)          | 18 (46.2)      | 0.82     |
| Schizoaffective disorders    |     | 9 (11.5)             | 5 (12.8)           | 4 (10.3)       | 0.72     |
| Bipolar disorders            | 78  | 18 (23.1)            | 12 (30.8)          | 6 (15.4)       | 0.11     |
| Depressive disorders         |     | 6 (7.7)              | 2 (5.1)            | 4 (10.3)       | 0.4      |
| Organic disorders            |     | 3 (3.9)              | 1 (2.6)            | 2 (5.1)        | 0.56     |
| Other                        |     | 6 (7.7)              | 2 (5.1)            | 4 (10.3)       | 0.4      |
| Not available                | 1 (1.3) | 0                     | 1 (2.6)            |                | 0.31     |
| Psychiatric illness duration, median (IQR), years | 65  | 6 (2–11)            | 8 (2–13)           | 6 (2–10)       | 0.42     |
| Medication, n (%)            | 78  |                      |                    |                |          |
| Amisulpride                  | 3 (3.9) | 0                     | 3 (7.7)            |                | 0.08     |
| Aripiprazole                 | 9 (11.5) | 5 (12.8)              | 4 (10.3)           |                | 0.72     |
| Clozapine                    | 4 (5.1)  | 2 (5.1)              | 2 (5.1)            |                | 1        |
| Lithium                      | 8 (10.3) | 5 (12.8)              | 3 (7.7)            |                | 0.46     |
| Mirtazapine                  | 3 (3.9)  | 2 (5.1)              | 1 (2.6)            |                | 0.56     |
| Olanzapine                   | 19 (24.4) | 8 (20.5)              | 11 (28.2)          |                | 0.43     |
| Quetiapine                   | 23 (29.5) | 13 (33.3)             | 10 (25.6)          |                | 0.46     |
| Risperidone                  | 8 (10.3) | 3 (7.7)               | 5 (12.8)           |                | 0.46     |
| Valproate                    | 1 (1.3)  | 1 (2.6)               | 0                  |                | 0.31     |
| Medication groups, n (%)³    | 78  |                      |                    |                |          |
| Low propensity for WG        | 12 (15.4) | 5 (12.8)              | 7 (18.0)           |                | 0.53     |
| Moderate propensity for WG    | 42 (53.9) | 23 (59.0)             | 19 (48.7)          |                | 0.36     |
| High propensity for WG       | 24 (30.8) | 11 (28.2)             | 13 (33.3)          |                | 0.62     |
| Baseline BMI, median (IQR), kg/m² | 77  | 22.3 (19.8–25.6)   | 23.5 (21.3–26.4)   | 21.9 (18.6–25.4) | 0.1      |
| BMI at first month, median (IQR), kg/m² | 77  | 23.8 (21.2–26.7)   | 23.7 (21.6–26.7)   | 23.9 (20.6–27.0) | 0.94     |
| Overweight prevalence (BMI ≥ 25 < 30 kg/m²), n(%) | 77  | 24 (31.2)            | 14 (36.8)          | 10 (25.6)      | 0.29     |
| p value⁴                     | 0.04 | 1                     | 0.04               |                |          |
| Obesity prevalence (BMI ≥ 30 kg/m²), n (%)  | 77  | 9 (11.7)             | 4 (10.5)           | 3 (7.7)        | 0.67     |
| p value⁴                     | 0.16 | 1                     | 0.16               |                |          |
| WG, median (IQR), %          | 78  | 3.8 (0–7.7)          | 0 (0–1.4)          | 7.7 (5.8–10.9) | < 0.0001 |

BMI body mass index, WG weight gain

¹Patients whose weight gain during the first month of treatment was between 0 and 2.5% were considered as controls, whereas patients whose weight gain during the first month of treatment was equal or higher than 5% were considered as cases

²p values were calculated using Wilcoxon rank-sum tests for continuous variables and χ² tests for categorical variables

³Amisulpride and aripiprazole were considered as drugs with a low propensity for WG; lithium, mirtazapine, quetiapine, and risperidone were classified in the group with moderate propensity for WG, whereas clozapine, olanzapine, and valproate were considered as having a high propensity for WG

⁴McNemar tests were conducted to test the difference between overweight and obesity between baseline and the first month of treatment.

Italic indicates significant p values
the proportion of overweight significantly increased in case patients (from 26% at baseline to 36% during the first month \((p = 0.04)\), whereas it remained stable in control patients (37% in both treatment periods)). Of note, reported appetite (ranging from weak, moderate, medium, elevated and very elevated and collected at baseline and after the first month of psychotropic treatment) was significantly increased during the first month of treatment \((n = 52; \ p = 0.048; \text{data not shown})\).

Pairwise \(t\) tests showed that during the first month of treatment, methylation levels in five probes localized in the \(CRTC1\) body region were significantly modified (Table 2). Thus, cg21310814, cg07015183, cg02961385, cg17006757, and cg22536770 significantly increased by 2, 0.8, 0.5, 0.9, and 0.4% \((n = 78; \ FDR \ p \text{ value} = 0.004, 0.004, 0.02, 0.048, \text{and} 0.048, \text{respectively})\). When stratifying the population into early weight gain patient groups, no significant modification of \(CRTC1\) methylation was observed in patients whose weight remained stable, whereas methylation modulations in three sites were observed in patients with important early weight gain (i.e., 0.8, −0.2, and 0.9% in cg07015183, cg12034943, and cg17006757; \(n = 39; \ FDR \ p \text{ value} = 0.02, 0.02, \text{and} 0.02\), respectively). Additional file 1: Figure S1 illustrates methylation levels of the abovementioned \(CRTC1\) probes according to the period of psychotropic treatment in the whole sample and in patients with early weight gain.

**Association of \(CRTC1\) methylation sites with early weight gain**

The six \(CRTC1\) methylation probes with significant changes during the first month of treatment (i.e., cg21310814, cg07015183, cg02961385, cg17006757, cg22536770, and cg12034943) (Fig. 1) were tested for association with early weight gain. In particular, multivariable linear mixed models with methylation levels as response adjusting for age, sex, psychotropic drug category, smoking status, treatment duration, and early weight gain group were fitted. In accordance with Additional file 1: Figure S1, Table 3 shows that methylation levels in cg21310814, cg07015183, cg02961385, cg17006757, and cg22536770 increased significantly with treatment duration \((p ≤ 0.02)\). In addition, a slight decrease of methylation in cg22536770 was observed with increasing age \((p = 0.04)\). In accordance with univariable analysis and as shown in Additional file 1: Figure S2, methylation decrease in cg12034943 during the first month of treatment was significant in cases \((p = 0.01)\) but not in control patients (Table 3). The latter was corroborated by an additional regression analysis considering the methylation change as an outcome (calculated as \((\text{methylation levels at first month} − \text{methylation levels at baseline})/\text{methylation levels at baseline}\))\((\text{value})\)\((\text{value})\)\((\text{value})\)\((\text{value})\). The former showed that methylation levels in cg12034943 significantly decreased during the first month of treatment and this decrease was mainly observed in patients with important early weight gain. This suggests that epigenetic change in cg12034943 could be related with psychotropic-induced weight gain.

**Secondary analyses: association of methylation in cg12034943 with metabolic parameters**

In order to further investigate the association between cg12034943 methylation and the pejoration of metabolic parameters during the first month of treatment, additional multivariable models considering metabolic parameters were conducted. In particular, BMI, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, and non-

### Table 2: Evolution of \(CRTC1\) methylation sites during the first month of psychotropic treatment

| Probe ID          | \(\beta\) at baseline, median (IQR) | \(\beta\) after 1 month, median (IQR) | \(p\) value | FDR \(p\) value \(^1\) |
|-------------------|-------------------------------------|--------------------------------------|-------------|-------------------------|
| All patients \((n = 78)\) |                                      |                                      |             |                         |
| cg21310814        | 81.7 (78.5–84.3)                    | 83.7 (81.2–84.9)                     | 0.00005     | 0.004                   |
| cg07015183        | 88.3 (87–89.5)                      | 89.1 (88–90.3)                      | 0.0001      | 0.004                   |
| cg02961385        | 94.7 (94.2–95.4)                    | 95.2 (94.7–96)                      | 0.0009      | 0.02                    |
| cg17006757        | 82.8 (80.4–84.2)                    | 83.7 (82–85.3)                      | 0.003       | 0.048                   |
| cg22536770        | 94.1 (93.3–94.7)                    | 94.5 (93.9–95.1)                    | 0.003       | 0.048                   |
| Controls \((n = 39)\) |                                      |                                      |             |                         |
| None              |                                      |                                      |             |                         |
| Cases \((n = 39)\) |                                      |                                      |             |                         |
| cg07015183        | 88.3 (87–89.5)                      | 89.1 (88–90.3)                      | 0.0006      | 0.02                    |
| cg12034943        | 7.4 (6.4–8.4)                       | 7.2 (6.5–8)                         | 0.0007      | 0.02                    |
| cg17006757        | 82.8 (80.4–84.2)                    | 83.7 (82–85.3)                      | 0.0008      | 0.02                    |

Only the sites with significant changes during the first month of treatment are shown. Of note, all significant methylation sites presented in this table are localized in the gene body region of \(CRTC1\).

\(\beta\) at baseline refers to methylation levels before starting the current psychotropic treatment.

\(\beta\) at first month refers to methylation levels after one month of treatment with psychotropic treatment.

Controls indicate patients whose weight remained stable during the first month of treatment.

Cases indicate patients with important (≥5%) early weight gain during the first month of treatment.

\(p\) values were calculated using paired \(t\)-tests. Probes are sorted by significance.

\(^1\) \(p\) values were adjusted using the false discovery rate approach.

None: No site with significant change during the first month was observed in control patients.
high-density lipoprotein cholesterol were tested separately for association with methylation levels in cg12034943. None of these metabolic parameters was associated with cg12034943 methylation during the first month of treatment (Additional file 1: Table S3). In addition, survival analyses showed no influence of this methylation site on overweight incidence (Additional file 1: Table S4). Of note, analyses on metabolic syndrome could not be conducted due to an insufficient number of complete observations (i.e., waist circumference, HDL cholesterol, triglycerides, glycemia, and/or blood pressure).

**Association between rs7258722T>A and cg12034943**

According to a recent study considering omics data from blood samples [49], cg12034943 is associated with CRTC1 rs7258722T>A, with individuals carrying the A-allele of this SNP having lower cg12034943 methylation values as compared to individuals carrying the TT genotype (p = 1.8 × 10^{-41}). In the present study, similar findings were observed in multivariable models considering a proxy of rs7258722T>A (i.e., rs4808844A>G, r^2 = 0.98) (p = 0.03) (Additional file 1: Table S5). Moreover, during the first month of treatment with psychotropic drugs, cg12034943 varied differently depending on the rs4808844A>G genotype. Thus, methylation in cg12034943 was not modified (p = 0.9) during the first month of treatment in patients carrying the AA genotype, whereas it decreased significantly (p = 0.006) in patients carrying the G allele (Additional file 1: Table S5). In addition, even when integrating this SNP (which is associated with cg12034943) in multivariable models on methylation outcome, the association between early weight gain and cg12034943 remained significant (Additional file 1: Table S5), suggesting independent and/or synergic influences of early weight gain and rs4808844A>G on cg12034943. When considering observations at the first month of treatment, a trend of interaction (p = 0.051) was observed between cg12034943 and rs4808844A>G genotypes on early weight gain groups, as illustrated by the Fig. 2. As a matter of fact, a significant association between early weight gain and cg12034943 was observed in patients carrying the G allele of rs4808844A>G (p = 0.03, Additional file 1: Table S5), while no association was identified in patients carrying the rs4808844A>G AA genotype. Early weight gain during treatment with psychotropic drugs therefore probably results from the interaction between genetic (rs4808844A>G) and epigenetic (cg12034943) factors. As rs4808844A>G is associated with cg12034943, this genetic variant was tested for association with early weight gain in a larger and independent sample of patients receiving psychotropic treatments known to induce metabolic disturbances but whose methylation data are not available (n = 172). Multivariable logistic regression showed a trend of association between rs4808844A>G and early weight gain, with patients carrying the G allele having less susceptibility of early weight gain as compared to patients carrying the AA genotype (Table 4). In addition, further analyses using generalized additive mixed models on weight in a larger cohort (n = 568) without available methylation data showed a trend of association between this SNP and weight, with patients carrying the G allele having lower weight values by 1.55 kg as compared to others (p = 0.07; Table 4). However, survival analyses showed no association between rs4808844A>G and overweight and/or obesity incidence in the later cohort (Additional file 1: Table S6).

**Discussion**

The present case-control longitudinal study aimed to determine whether psychotropic drugs could induce methylation modulations in CRTC1 gene during the first month of treatment and to assess if these methylation changes were associated with an important early weight gain (≥ 5%) during the same period.
We identified relationships between methylation and early weight gain during the first month of treatment. Our study included 151 patients who were treated with psychotropic drugs. We found that methylation at cg12034943 was associated with early weight gain, even after adjusting for age, sex, psychotropic drug category, smoking status, and treatment duration. This association was independent of the rs4808844A>G genotype.

Table 3: Association between CRTC1 methylation probes and psychotropic induced-early weight gain during the first month of treatment

| Probe          | Estimate (SE) | p value | Estimate (SE) | p value | Estimate (SE) | p value | Estimate (SE) | p value | Estimate (SE) | p value |
|----------------|---------------|---------|---------------|---------|---------------|---------|---------------|---------|---------------|---------|
| cg21310814 (%) | NS            | NS      | NS            | NS      | NS            | NS      | NS            | −0.3 (0.2) | 0.01         |
| cg07015183 (%) | NS            | NS      | NS            | NS      | NS            | NS      | NS            | NS      | NS            |
| cg02961385 (%) | NS            | NS      | NS            | NS      | NS            | −0.008 (0.006) | 0.04 | NS            |
| cg17006757 (%) | NS            | NS      | NS            | NS      | NS            | NS      | NS            | NS      | NS            |
| cg22536770 (%) | NS            | NS      | NS            | NS      | NS            | NS      | NS            | NS      | NS            |
| cg12034943 (%) | NS            | NS      | NS            | NS      | NS            | NS      | NS            | NS      | NS            |

Multivariable models adjusting for age, sex, psychotropic drug category, smoking status, and treatment duration were fitted for 151 observations (from 78 patients). Models on M values were conducted to determine the p values, whereas models on beta values were conducted to determine the estimates. Validity of multivariable models was verified by plotting residuals against fitted values. Additional multivariable models considering the white blood cell composition were fitted for 68 patients. Neutrophils were significantly associated with cg21310814, cg17006757, and cg12034943 (p < 0.001, p = 0.003, and p = 0.04). Associations between all CRTC1 probes and variables indicated in this table remained significant when adjusting for white blood cell composition (except for cg17006757). p values in italic are significant.

NS non-significant

1 Patients whose weight gain during the first month of treatment was between 0 and 2.5% were considered as controls, whereas patients whose weight gain during the first month of treatment was equal or higher than 5% were considered as cases.

2 Psychotropic drugs were categorized into three groups according to their weight gain propensities: amisulpride and aripiprazole were considered as drugs with a low propensity for weight gain, lithium, mirtazapine, quetiapine, and risperidone were considered as drugs with a moderate propensity for weight gain and clozapine, olanzapine, and valproate were considered as having a high risk for inducing weight gain.

3 Treatment duration was considered in days.

To the best of our knowledge, cg12034943 methylation site has been described only once, in a subgroup of the Framingham Heart Study (blood samples from 2567 individuals), where it was associated with symptomatic coronary heart disease [53]. However, no mechanism was proposed and since this study was transversal, no causal inference could be drawn. Most interestingly, in a recent genome-wide association meta-analysis on body fat percentage conducted in more than 100,000 individuals from the general population, CRTC1 reached genome-wide significance and epigenetic mechanisms were suggested to explain this association [48]. In particular, rs4808844 and rs4808845 were identified as the variants with the greatest amount of regulatory functions, including open chromatin, histone marks that are characteristic of active transcription regulation, and RNA polymerase II binding. Thus, the latter study showed that rs4808844 was significantly associated with RNA polymerase II binding signal strength [48]. In addition, DNaseI hypersensitivity in this genetic region has been shown to correlate negatively with transcription levels of CRTC1 and of cytokine receptor like factor 1 (CRLF1) in many cell types [54]. Eventually, rs4808844 and its proxies may affect the expression of multiple genes in different tissues, including the ceramide synthase 1 (CERS1) in the adrenal gland [50], a gene which has been involved in the regulation of metabolic factors such as obesity-induced insulin resistance [55] and fat metabolism [56]. Taken together, these elements suggest...
that together with cg12034943, rs4808844 may influence the expression of CRTC1, a gene previously described to be associated with metabolic features in the psychiatric population [38, 47].

Although we have not assessed whether the small methylation change of cg12034943 was associated with transcriptional modifications (e.g., of CRTC1), small magnitudes of effect (from 2 to 10%, or even smaller [57–60]) resulting from environmental exposures are often observed in environmental epigenetic studies [57] and these small DNA methylation changes may reflect larger changes in chromatin structure and could be associated with broader changes in gene expression [57, 61]. In agreement with that assumption, cg12034943 lies in the intronic region of CRTC1 and, according to the “regulome” database and to a previous study [48], it is localized in a highly regulated region of open chromatin and in a binding region of a RNA polymerase II. The functional biological significance of methylation change in this genetic region should be assessed by future studies. Of note, although being in a lower range, we can consider that our methylation differences of around 0.7% measured after only a month of treatment in case patients carrying the rs4808844 G allele is consistent with methylation differences observed in previous environmental epigenetic studies that compared life-long methylation differences between exposed versus non-exposed patient groups [57].

Some limitations of the present study should be considered. Even if conducted in longitudinal settings, this

Table 4 Association between rs4808844A>G and weight parameters in an independent psychiatric sample without available methylation data

|                      | Early weight gain | Weight (kg) | 
|----------------------|-------------------|-------------|
|                      | Estimate (SE)     | p value     | Estimate (SE)     | p value     |
| rs4808844 A>G [G]    | 131 – 0.66 (0.40) | 0.10        | 568 – 1.55 (1.2)  | 0.07        |

1 A logistic model adjusting for age, sex, psychotropic drug category, smoking status, and treatment duration was fitted in patients with available genetic data for rs4808844 and with available weight at baseline and after the first month of treatment

2 A GAMM adjusting for age, sex, psychotropic drug category, smoking status, and treatment duration was fitted in patients with available weight and genetic data for rs4808844
study did not allow to determine whether psychotropic drug-induced methylation modulations promoted early weight gain or if psychotropic drug-induced early weight gain promoted the observed methylation change. Such a causal inference could be conducted in future studies using Mendelian randomization, a tool which can be used in this sort of analysis but which usually requires an important sample size (e.g., > 10,000) [62]. In addition, because weight gain induced by psychotropic drugs is mainly mediated by an appetite increase driven by hypothalamic cues, we supposed that the methylation levels observed in blood would reflect methylation changes occurring in the brain. Although brain samples of patients starting a psychotropic medication were not available, a recent study conducted in subjects with medically intractable epilepsy undergoing neurosurgery showed that levels of cg12034943 methylation are comparable in the blood and in the brain [63]. Of note, studies on methylation changes are only feasible using peripheral tissues since postmortem brain samples are available at only one time point, while neurosurgery procedures as in the abovementioned study [63] are expected to occur only once in most if not all cases. It is also noteworthy that, in the present study, continuous BMI was not associated with cg12034943 methylation change. This can probably be explained by our case-control study design, which altered the BMI distribution. Besides, future studies on cg12034943 methylation in patients who lose weight after stopping a psychotropic treatment inducing metabolic disturbances should enable to determine whether change of this methylation site goes in the opposite direction. Moreover, modulations of microRNA levels induced by psychotropic drugs such as antipsychotics [64], mood stabilizers [65–67] and some antidepressants [68] may also be involved in metabolic side effects and should be considered in future studies. Even if a recent study showed that DNA methylation is a better predictor of chronic alterations than RNA expression which seems to fluctuate more in acute conditions [69], research placing emphasis on gene transcription markers would probably help to further understand mechanisms underlying metabolic side effects induced by psychotropic medications.

Conclusions
In conclusion, the present study identified a methylation change during the first month of psychotropic treatment in the CRTC1 gene, which was associated with early weight gain during the same period. This epigenetic modulation was dependent on a genetic variant in the same genetic region, which plays a considerable regulatory role. These findings give new insights on psychotropic-induced weight gain and underline the need for future studies considering the combination of genome-wide association studies (GWAS), epigenome-wide association studies (EWAS), and transcription data in order to disentangle the complex mechanisms involved in psychotropic-induced side effects.

Methods
Study population
Since 2007, a longitudinal observational study (PsyMetab) has been ongoing at the Department of Psychiatry of the Lausanne University Hospital as described elsewhere [38]. Patients with informed consent starting a psychotropic treatment known to have a potential risk to induce metabolic disturbances (i.e., antipsychotics, mood stabilizers, and some antidepressants, as listed in Additional file 1: Table S7) were included. More details in Additional file 1.

Case and control patients
A threshold of 5% of weight gain during the first month of treatment was shown to be the best predictor of important weight gain in the longer-term of treatment [70]. Therefore, among PsyMetab patients, those with a weight gain equal or higher than 5% during the first month of treatment were considered as cases, whereas matched (for age, sex, baseline BMI, and medication) PsyMetab patients whose weight remained stable (i.e., weight change between 0 and 2.5%) were considered as controls. Therefore, a total of 39 case and 39 control patients were considered for methylation analyses. Of note, PsyMetab patients with moderate weight loss (e.g., from −2.5% to 0) were not included in the present study because the observed weight loss could be attributed to a switch from a high risk drug to a drug with a lower propensity for inducing weight gain, which was not of interest for the present study.

PsyMetab patients without available methylation data
PsyMetab patients whose methylation levels were not available were considered in analyses on the association between a CRTC1 SNP (rs4808844A>G) and metabolic disturbances induced by psychotropic treatment (e.g., weight gain). Methylation analyses were not conducted in this sample because of a weight loss, an “intermediate” weight gain (between 2.5% and 5%) or because of missing data in at least one important variable to take into account in methylation analyses (age, sex, baseline BMI, medication group, or smoking status).

DNA methylation array
Two blood samples for each of the 78 case and control patients were collected (i.e., the first was retrieved before starting the psychotropic treatment and the second was drawn 1 month after starting the psychotropic treatment), from which DNA methylation was analyzed using the Illumina Infinium Methylation EPIC BeadChip (Illumina, San Diego, CA, USA). More details are in Additional file 1.
Longitudinal changes in DNA methylation were analyzed for 76 CpG loci in CRTC1 (as listed in Additional file 1: Table S1), by considering M values. The M value is calculated as the log2 ratio of the intensities of methylated probe versus unmethylated probe. While a M value close to 0 means that the CpG is half-methylated, a positive M value means that the CpG has more methylated than unmethylated cytosines and a negative M value indicates the opposite ratio [71, 72]. Although the beta-value has a more intuitive biological interpretation, the M value is more statistically valid for the differential analysis of methylation levels [72]. Then, as proposed by Du et al. [72], M values were used for conducting the differential methylation analyses (and to calculate the p values), whereas beta-values were reported in the estimate section of the results.

Genotyping
A cis-meQTL SNP of interest (i.e., rs4808844A>G) was obtained from the Illumina 200K CardiometaboChip (Illumina, San Diego, California, USA) [73] at the iGE3 genomics platform of the University of Geneva (http://www.ige3.unige.ch/genomics-platform.php).

Statistical analysis
Wilcoxon Mann-Whitney rank-sum tests and chi-squared tests were conducted to compare continuous and categorical variables, respectively, across patient groups.

McNemar tests were conducted to evaluate the prevalence differences in certain variables between baseline and the first month of treatment. Paired t tests were used to determine the difference of methylation levels between baseline and the first month of treatment. In order to adjust for multiple comparisons (n = 76), p values were adjusted using the false discovery rate (FDR) approach. Multivariable linear and generalized linear mixed effect models were also used to assess differences among individuals in two groups while adjusting comparisons for potential covariates and cofactors. The fit adequacy was assessed using visual tools. Of note, additional multivariable models adjusting for cell-type composition (i.e., percent neutrophils measured in blood samples) were also conducted. Generalized additive mixed models were used for testing the association between CRTC1 rs4808844 and weight parameters in an independent psychiatric sample (n = 568) of patients starting a psychotropic treatment inducing metabolic disturbances (without available methylation data). These models are powerful and flexible tools useful in capturing highly non-linear trends in time. Functional assessment of methylation sites and SNPs is described in Additional file 1. Statistical significance was defined as a p value ≤ 0.05. Statistical analyses were performed using Stata 14 (StataCorp, College Station TX, USA) and R environment for statistical computing version 3.3.1. More details are available in Additional file 1.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13148-019-0792-0.

Additional file 1. Supplementary data.

Abbreviations
CERS1: Ceramide synthase 1; CRLF1: Cytokine receptor-like factor 1; CRTC1: CREB-regulated transcription coactivator 1; EWAS: Epigenome-wide association studies; GWAS: Genome-wide association studies; meQTL: Methylation quantitative trait loci; SNPs: Single nucleotide polymorphisms

Acknowledgements
The authors are grateful to C. Brogli and C. Darbellay for the logistical assistance; E. Retamales for bibliographical help; and A.-C. Aubert, A. Vuilloud, G. Viret, M. Brawand, M. Brocard, M. Delessert, N. Cochard, and S. Jaquet for sample analysis. The authors thank the nursing and medical staff who were involved in the metabolic monitoring program.

Authors’ contributions
CE conceptualized the study; AD and CE designed the work; AD, AG, CD, AVG, and PC were involved in data acquisition; AD drafted the manuscript and analyzed the data. AD, MGR, JVS, JG, and CE interpreted the data. All authors have approved the submitted version and have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Funding
This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 320030-120686, 324730-144064, and 320030-173211). The funding sources had no role in the writing of the manuscript or in the decision to submit it for publication.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was carried out in accordance with the Declaration of Helsinki, the good epidemiological practice written by the Swiss Society of public health, and the Swiss law and local requirements. The study protocol, numbered 2017-01301, was approved by the Ethic committee of Vaud (CER_VD) with written informed consent from all subjects.

Consent for publication
Not applicable.

Competing interests
CBE received honoraria for conferences or teaching CME courses from Forum für Medizinische Fortbildung, Janssen-Cilag, Lundbeck, Mepra, Otsuka, Sandoz, Servier, Vifor-Pharma, and Zeller in the past 3 years, and for writing a review article for the journal “Dialogues in clinical neurosciences” (Servier). He received an unrestricted educational research grant from Takeda in the past 3 years. AVG received honoraria for a conference or workshop participation from Vifor and Schwabe in the previous 3 years. All authors declare no conflict of interest in relation to the content of the paper.
Author details
1Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 2Centre of Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 3Laboratory of Neuropsychogenetics, Brain Mind Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. 4Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 5Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 6Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Received: 21 July 2019 Accepted: 2 December 2019
Published online: 26 December 2019

References
1. Baccarelli A, Rienstra M, Benjamin EJ. Cardiovascular epigenetics: basic concepts and results from animal and human studies. Circ Cardiovasc Genet. 2010;3(6):567–73.
2. Wilson LE, Harkel S, Xu Z, Sandler DP, Taylor JA. An epigenome-wide study of body mass index and DNA methylation in blood using participants from the Sister Study cohort. Int J Obes. 2017;41(1):194–9.
3. Mendelson MM, Mationi RE, Joehanes R, Liu C, Hedman AK, Aslibekyan S, et al. Association of body mass index with DNA methylation and gene expression in blood cells and relations to cardiometabolic disease: a genome-wide association study of body mass index and the adverse outcomes of adiposity. Nature. 2017;541(7635):81–6.
4. Zhong J, Agha G, Baccarelli AA. The role of DNA Methylation in cardiovascular risk and disease: methodological approaches, study design, and data analysis for epidemiological studies. Circ Res. 2016;118(1):119–31.
5. Dick KJ, Nelson CP, Tsaprouni L, Sandling JK, Aissi D, Wahl S, et al. DNA methylation and body mass index: a genome-wide analysis. Lancet (London, England). 2014;383(9933):1990–8.
6. Hjorthøj C, Surup AE, McGrath JJ, Nordenfelt M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301.
7. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–41.
8. Khan A, Faucett J, Morrison S, Brown WA. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry. 2013;70(10):1091–9.
9. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97–107.
10. De Hert M, Detraux J, van Winkel R, Wu Y, Correll CU. Metabolic and cardiovascular adverse effects associated with atypical antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–26.
11. MacNeil RR, Muller DJ. Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry. 2016;2(2):61–71.
12. Correll CU, Detraux J, De Lepelere J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):19–36.
13. Diaz FJ, Perez-Iglesias R, Mata L, Martinez-Garcia O, Vazquez-Barquero JL, de Leon J, et al. Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-naive first-episode psychosis patients. Schizophrenia Res. 2011;131(3):382–9.
14. Guesdon B, Denis RG, Richard D. Additive effects of olanzapine and melatonin-concentrating hormone agonism on energy balance. Behav Brain Res. 2010;207(1):114–20.
15. Westen-Green Koniaris FY, Deng C. Alterations to melancortinergic, GabAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS One. 2012;7(3):e33548.
16. Melia MG, Lafer BI, McDonald P, Castellani CA, Rajakumar N, O’Reilly R, et al. The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum. Clin Epigenet. 2014;6(1):1.
17. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A. 2008;105(36):13614–9.
18. Sugawara H, Bundu M, Asai T, Sunaga F, Ueda J, Ishigooka J, et al. Effects of quetiapine on DNA methylation in neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry. 2015;56:117–21.
19. Asai T, Bundu M, Sugawara H, Sunaga F, Ueda J, Tanaka G, et al. Effect of mood stabilizers on DNA methylation in human neuroblastoma cells. Int J Neuropsychopharmacol. 2013;16(10):2285–94.
20. D’Addario C, Dell’Osso B, Palazzo MC, Benatti B, Lietti L, Cattaneo E, et al. Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology. 2012;37(7):1642–55.
21. Milutinovic S, D’Alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis. 2007;28(3):560–71.
22. Melas PA, Rogdaki M, Ousby S, Schalling M, Lavebbrat C, Ekstrom T. Epigenetic alterations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J. 2012;26(6):2712–8.
23. Burghardt KJ, Goodrich JM, Dolinoy DC, Ellingrod VL. Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance. Bipolar Disord. 2016;18(5):423–32.
24. Burghardt KJ, Goodrich JM, Dolinoy DC, Ellingrod VL. DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder. Epigenomics. 2015;7(3):342–52.
25. Vandenberghe F, Ghollam-Rezaee M, Saiji-Morgui N, Delacretaz A, Choong E, Solida-Tozzi A, et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry. 2015;76(11):e1417–23.
26. Delacretaz A, Vandenberghe F, Ghollam-Rezaee M, Saiji-Morgui N, Glarad A, Thorne J, et al. Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. J Clin Lipidol. 2018;12(1):219–20.
27. Sihra VH, Phutane VH, Oskan B, Chwastak L, Ratliff JC, Woods SW, et al. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. Schizophrenia Res. 2013;146(3–4):64–8.
28. Burghardt KJ, Seyourn B, Mallisho A, Burghardt PR, Kowluur RA, Yi Z. Atypical antipsychotics, insulin resistance and weight: a meta-analysis of healthy volunteer studies. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:55–63.
29. Choong E, Solida A, Lechare C, Conus P, Eap CB. Follow-up of the metabolic syndrome induced by antipsychotic antidepressants: recommendations and pharmacogenetics perspectives. Rev Med Suisse. 2008;4:1711–94–9.
30. El Asmar K, Feve B, Colle R, Trabado S, Verstuyft C, Gressier F, et al. Early phase weight gain associated with later metabolic syndrome in depressed patients treated with antidepressants: findings from the METADAP cohort. J Psychiatr Res. 2018;107:120–7.
31. Ryu S, Cho EY, Park T, Oh S, Jang WS, Kim SK, et al. 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antidepressive drug treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):673–7.
32. Salt SL, Galloway GP, Baggott MJ, Schwartz Z, Mendelson J. Mechanisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol Ther. 2011;90(1):179–83.
33. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17(3):242–66.
34. Saiji-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Choong E, Ghollam-Rezaee M, et al. Association of PCK1 with body mass index and other metabolic features in patients with psychotropic treatments. J Clin Psychiatry. 2015;85:S54–52.
35. Quteineh L, Vandenberghe F, Saiji-Morgui N, Delacretaz A, Choong E, Ghollam-Rezaee M, et al. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic drug treatments. Pharmacogenomics. 2015;16(3):246–58.
36. Delacretaz A, Preissig M, Vandenberghe F, Saiji-Morgui N, Quteineh L, Choong E, et al. Influence of MCHR2 and MCHR2-AS1 genetic polymorphisms on body mass index in psychiatric patients and in population-based subjects with present or past atypical depression. PLoS One. 2015;10(10):e0139155.
38. Choong E, Quteineh L, Cardinaux JR, Gholam-Rezaee M, Vandenbergh F, Dobrinas M, et al. Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population. JAMA Psychiatry. 2013;70(10):1011–9.

39. Alatarogui JY, Goebel N, Conkright MD, Huse H, Xie J, Arias CM, et al. The CEB1/CREB1 transactivator CRTC1 is required for energy balance and fertility. Nat Med. 2008;14(10):1112–7.

40. Breuleaud L, HALFON M, Magistretti PJ, Pralong FP, Cardinaux JR. Mouse fertility is not dependent on the CREB coactivator CRTC1. Nat Med. 2009;15(9):899–90 author reply 91.

41. Kim H. The transcription cofactor CRTC1 protects from aberrant hepatic lipid accumulation. Sci Rep. 2016;6:37280.

42. Rossetti C, Sciarra D, Petit JM, Eap CB, Halfon O, Magistretti PJ, et al. Gender-specific alteration of energy balance and circadian locomotor activity in the Crtc1 knockout mouse model of depression. Transl Psychiatry. 2017;7(12):1269.

43. Breuleaud L, Rossetti C, Meylan EM, Meinaut C, Halfon O, Magistretti PJ, et al. Deletion of CREB-regulated transcription coactivator 1 induces pathological aggression, depression-related behaviors, and neuroplasticity genes dysregulation in mice. Biol Psychiatry. 2012;72(7):528–36.

44. Bornstein SR, Schuppenies A, Wong ML, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions. Mol Psychiatry. 2006;11(10):892–902.

45. Soczyńska J, Kennedy SH, Woldeyohannes HO, Liaw SS, Alsuwaidan M, Yim CY, et al. Modd disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuroumolecular Med. 2013;13(2):93–116.

46. Rossetti C, Halfon O, Boutez B. Controversies about a common etiology for eating and mood disorders. Front Psychol. 2014;5:1205.

47. Quteineh L, Preisig M, Rivera M, Milanesci Y, Castelao E, Gholam-Rezaee M, et al. Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression. J Affect Disord. 2016;194:83–9.

48. Lu Y, Day FR, Gustafsson S, Buchkovich ML, Na J, Bataille V, et al. New loci selective inhibitor of ceramide synthase 1 reveals a novel role in fat metabolism. Nat Commun. 2018;9(1):3165.

49. Bonder MJ, Luijk R, Zhernakova DV, Moed M, Deelen P, Vermaat M, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2015;47(5):635–41.

50. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–5.

51. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22(9):1790–801.

52. Do C, Shearer A, Suzuki M, Terry MB, Gelernter J, Greally JM, et al. Epigenetic interactions in cis: a major focus in the post-GWAS era. Genome Biol. 2017;18(1):120.

53. Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. A strategy for establishing the causal role of epigenetic processes in pathways to disease. Int J Epidemiol. 2012;41(1):161–76.

54. Braun PR, Han S, Hing B, Nagahama Y, Gaul LN, Heinzman JT, et al. Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals. Transl Psychiatry. 2019;9(1):147.

55. Gardner E, Carroll A, Tooney PA, Cairns MJ. Antipsychotic drug-associated gene-miRNA interaction in T-lymphocytes. Int J Neuropsychopharmacol. 2014;17(6):929–43.

56. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahlon A, Wei Y, et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology. 2009;34(6):1395–405.

57. Chen H, Wang N, Burmeister M, McInnis MG. MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol. 2009;12(7):975–81.

58. Hunsberger JG, Fesler EB, Chibane FL, Leng Y, Marc D, Elkahlon AG, et al. Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions. Am J Transl Res. 2013;5(4):450–64.

59. Bocchio-Chiavetto L, Maffioletti E, Bettinelli P, Giovannini C, Bignotti S, Tarallo D, et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2013;23(7):602–11.

60. Chen R, Xia L, Tu K, Duan M, Kuburka K, Li-Pook-Than J, et al. Longitudinal personal DNA methyleme dynamics in a human with a chronic condition. Nature Med. 2018;24(12):1930–9.

61. van Dijk SJ, Tellam RL, Morrison JL, Mulhuisler BS, Molloy PL. Recent developments on the role of epigenetics in obesity and metabolic disease. Clin Epigenet. 2015;7:66.

62. Reitn CL, Davey SG. Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. Int J Epigenet. 2012;4(1):161–76.

63. van Dijk SJ, Tellam RL, Morrison JL, Mulhuisler BS, Molloy PL. Recent developments on the role of epigenetics in obesity and metabolic disease. Clin Epigenet. 2015;7:66.

64. van Dijk SJ, Tellam RL, Morrison JL, Mulhuisler BS, Molloy PL. Recent developments on the role of epigenetics in obesity and metabolic disease. Clin Epigenet. 2015;7:66.